MajorTriptan, selective 5HT1B/1D receptor agonist×Second-generation systemic triazole antifungal
Updated · Methodology
Mechanism
The liver breaks down eletriptan mainly through the enzyme CYP3A4, and the posaconazole label describes posaconazole as a strong inhibitor of this enzyme. No study has looked at this pair directly, but other strong CYP3A4 inhibitors raised eletriptan levels markedly. Ketoconazole 400 mg increased the eletriptan area under the curve (AUC) 5.9-fold and lengthened its half-life from 4.8 to 8.3 hours. Erythromycin 1000 mg increased the AUC 3.6-fold. The body clears posaconazole slowly: the mean half-life of the tablets is 29 hours. Like other triptans, eletriptan can cause coronary artery spasm and a rise in blood pressure. High blood pressure is also a common adverse reaction to posaconazole itself.
Symptoms
Tightness, pain or pressure in the chest, throat, neck and jaw is common after eletriptan. It is usually not cardiac but can be a sign of coronary artery spasm. Myocardial infarction, ventricular tachycardia and ventricular fibrillation have been reported within a few hours of triptan use, sometimes in people without known heart disease. Rarely, blood pressure rises sharply, even to a hypertensive crisis. Spasm of other arteries can cause abdominal pain with bloody diarrhoea from bowel ischaemia, white and cold fingers (Raynaud's syndrome), or cramping and heaviness in the legs.
Management
The eletriptan summary of product characteristics (SmPC) says not to use eletriptan with strong inhibitors of the enzyme CYP3A4 (Spanish Agency of Medicines and Medical Devices, AEMPS). Posaconazole is a strong inhibitor of this enzyme (posaconazole SmPC, European Medicines Agency, EMA). The eletriptan label of the US Food and Drug Administration (FDA) requires a gap of at least 72 hours after treatment with a strong CYP3A4 inhibitor. Eletriptan is contraindicated in severe or moderately severe hypertension and in untreated mild hypertension (eletriptan SmPC, AEMPS). Monitor blood pressure and potassium during posaconazole treatment, because posaconazole can rarely cause pseudoaldosteronism with high blood pressure and low potassium (posaconazole label, FDA). If eletriptan has been taken during posaconazole treatment and chest pain or tightness suggesting cardiac ischaemia appears, give no further doses and evaluate the heart (eletriptan SmPC, AEMPS). Stop eletriptan if arrhythmias occur (eletriptan label, FDA). If signs of spasm in other arteries appear, such as abdominal pain with blood in the stool or white, cold fingers, rule out vasospasm before the next dose (eletriptan label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Relpax (eletriptan hydrobromide) tablets – prescribing information (2024)– FDA label, Viatris Specialty, DailyMed setid 2a501dbd-3ea8-47e4-9fcb-07035b8c8c9e, version 4, 01/2024, sections 4, 5.7, 7.1, 7.2 and 7.3
- FDA: Noxafil (posaconazole) prescribing information (2026)– FDA, DailyMed, Noxafil (Merck Sharp & Dohme), setid b073b082-7b57-4423-8c06-4fd4263d6f84, versión 56, revisión 02/2026, secciones 4.2, 4.3, 4.4, 4.5, 5.2 y 7.2
- AEMPS: Ficha técnica de Noxafil 100 mg comprimidos gastrorresistentes (posaconazol) (2026)– AEMPS, CIMA (texto EMA), nº registro 105320002, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Eletriptán (nº registro 64124), sección 4.5 (2024)– AEMPS, CIMA, nº registro 64124 (Relpax 20 mg, Viatris), revisión 05/2024, secciones 4.4 y 4.5